Effect of Tiotropium (Spiriva) on Exercise Tolerance in COPD Patients

PHASE3CompletedINTERVENTIONAL
Enrollment

261

Participants

Timeline

Start Date

October 10, 2000

Primary Completion Date

January 7, 2003

Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
DRUG

tiotropium bromide

Trial Locations (28)

Unknown

St. Elizabeth's Medical Center of Boston, Boston

Mayo Clinic, Rochester

St. Thomas Health Services, Nashville

Presbyterian Hospital of Dallas, Dallas

Phase I Unit, Randwick

Immunology Department, Westmead

Department of Respiratory Medicine, Daw Park

The Queen Elizabeth Hospital, Woodville

Department of Respiratory Medicine, Heidelberg

Respiratory Research, Calgary

University of Alberta, Edmonton

Respiratory Clinic, Vancouver

Boehringer Ingelheim Investigational Site, Halifax

Cardio Repiratory, Hamilton

Kingston General Hospital, Kingston

1053 Carling Avenue, Ottawa

Department of Respiratory Medicine, Toronto

University Health Network - Toronto General Hospital, Toronto

Montreal Chest Institute - McGill University Health Centre, Montreal

Pulmonary Function Lab, Montreal

Hopital Laval, Ste-Foy

Boehringer Ingelheim Investigational Site, Saskatoon

Klinikum der Universität zu Köln, Cologne

Pneumologisches Forschungsinstitut GmbH am Krankenhaus, Hamburg

Fraunhofer-Institut für Toxikologie und, Hanover

Universitätsklinikum Schleswig-Holstein, Kiel

Neurologische Klinik der Otto-von-Guericke-Universität, Magdeburg

Boehringer Ingelheim Investigational Site, München

Sponsors
All Listed Sponsors
lead

Boehringer Ingelheim

INDUSTRY